TF-1a (ATCC® CRL-2451)

Organism: Homo sapiens, human  /  Tissue: bone marrow  /  Cell Type: erythroblast

Permits Notice: Necessary Permits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Organism Homo sapiens, human
Tissue bone marrow
Cell Type erythroblast
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Disease erythroleukemia
Age 35 years
Gender male
Ethnicity Japanese
Applications
It can be used to study signal pathways involved in the spontaneous and factor-induced growth of the cells.
Storage Conditions liquid nitrogen vapor phase
Clinical Data
35 years
Japanese
male
Antigen Expression
CD34+, CD38-
Genes Expressed
CD34+, CD38-
Tumorigenic Yes
Comments
TF-1a is a factor-independent variant isolated from the factor-dependent TF-1 cell line (see CRL-2003).
The cells retain the ability to respond to a variety of cytokines, with a different response pattern from the parental cell line.
TF-1a, but not TF-1 cells, form colonies in soft agar culture in the absence of any added growth factors, and generate invasive tumors in nude mice.
There is a slight constitutive activation of the MAP kinase and MEK proteins in TF-1a but not in TF-1 cells. Phenotypically, TF-1 cells are CD34 positive and CD38 positive, whereas TF-1a cells are CD34 positive and CD38 negative.
TF1-a cells, but not TF-1 cells, are resistant to tumor necrosis factor alpha (TNF-alpha) induced apoptosis.
TF-1a is a model for studying human primitive myeloid progenitor cells and for studying the process of progressive malignant transformation of myeloid cells.
It can be used to study signal pathways involved in the spontaneous and factor-induced growth of the cells.
A culture submitted to the ATCC in April of 1999 was found to be contaminated with mycoplasma. Progeny were cured by a 21-day treatment with BM Cycline.
The cells were assayed for mycoplasma, by the Hoechst stain, PCR and the standard culture test, after a six-week period following treatment. All tests were negative.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 3 X 105 viable cells/mL.
Maintain cell density between 3 X 105 and 3 X 106 viable cells/mL.
Cryopreservation
culture medium 95%; DMSO, 5%
Culture Conditions
Temperature: 37°C
STR Profile
Amelogenin: X,Y
CSF1PO: 13
D13S317: 8,9
D16S539: 9,12
D5S818: 13
D7S820: 12
THO1: 7,9
TPOX: 8
vWA: 15,17
Name of Depositor X Hu
References

Hu X, et al. Characterization of a unique factor-independent variant derived from human factor-dependent TF-1 cells: a transformed event. Leuk. Res. 22: 817-826, 1998. PubMed: 9716013

Permits Notice: Necessary Permits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Hu X, et al. Characterization of a unique factor-independent variant derived from human factor-dependent TF-1 cells: a transformed event. Leuk. Res. 22: 817-826, 1998. PubMed: 9716013